Aiforia Technologies Plc, Company Release, Managers’ Transactions, March 12, 2026 at 13:00 EET

Aiforia Technologies Plc – Managers’ Transactions – Tuomas Tenkanen

Aiforia Technologies Plc has received a notification from Tuomas Tenkanen, Aiforia Technologies Plc's Board Member, of a transaction made with Aiforia Technologies Plc’s financial instrument, according to the Article 19 of EU Market Abuse Regulation. Detailed information about the transaction is given here under.

____________________________________________

Aiforia Technologies Plc - Managers' transactions - Tenkanen

____________________________________________

Person subject to the notification requirement

Name: TJT Technologies Oy

Position: Chief Executive Officer

(X) Legal person (1):Person Discharging Managerial Responsibilities In Issuer

Name: Tuomas Tenkanen

Position: Member of the Board

Issuer: Aiforia Technologies Oy

LEI: 743700TJRVBX7420Y723

Notification type: INITIAL NOTIFICATION

Reference number: 146827/4/8

____________________________________________

Transaction date: 2026-03-10

Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)

Instrument type: SHARE

ISIN: FI4000507934

Nature of transaction: ACQUISITION

Transaction details

(1): Volume: 507 Unit price: 1.795 EUR

(2): Volume: 2999 Unit price: 1.795 EUR

(3): Volume: 1200 Unit price: 1.795 EUR

(4): Volume: 3000 Unit price: 1.795 EUR

(5): Volume: 6312 Unit price: 1.785 EUR

Aggregated transactions (5):

Volume: 14018 Volume weighted average price: 1.7905 EUR

____________________________________________

Transaction date: 2026-03-10

Venue: POSIT (XPOS)

Instrument type: SHARE

ISIN: FI4000507934

Nature of transaction: ACQUISITION

Transaction details

(1): Volume: 9911 Unit price: 1.79 EUR

Aggregated transactions (1):

Volume: 9911 Volume weighted average price: 1.79 EUR

____________________________________________

Transaction date: 2026-03-11

Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)

Instrument type: SHARE

ISIN: FI4000507934

Nature of transaction: ACQUISITION

Transaction details

(1): Volume: 90 Unit price: 1.8 EUR

(2): Volume: 10 Unit price: 1.795 EUR

(3): Volume: 500 Unit price: 1.795 EUR

(4): Volume: 500 Unit price: 1.795 EUR

(5): Volume: 3400 Unit price: 1.795 EUR

(6): Volume: 5065 Unit price: 1.795 EUR

(7): Volume: 500 Unit price: 1.795 EUR

(8): Volume: 400 Unit price: 1.795 EUR

(9): Volume: 35 Unit price: 1.795 EUR

(10): Volume: 6100 Unit price: 1.795 EUR

(11): Volume: 500 Unit price: 1.795 EUR

(12): Volume: 4500 Unit price: 1.795 EUR

(13): Volume: 500 Unit price: 1.795 EUR

(14): Volume: 500 Unit price: 1.795 EUR

(15): Volume: 2500 Unit price: 1.795 EUR

(16): Volume: 500 Unit price: 1.795 EUR

(17): Volume: 1500 Unit price: 1.795 EUR

(18): Volume: 365 Unit price: 1.795 EUR

(19): Volume: 635 Unit price: 1.795 EUR

(20): Volume: 571 Unit price: 1.795 EUR

(21): Volume: 2330 Unit price: 1.785 EUR

(22): Volume: 270 Unit price: 1.785 EUR

Aggregated transactions (22):

Volume: 31271 Volume weighted average price: 1.79418 EUR

____________________________________________

Transaction date: 2026-03-11

Venue: DNFI

Instrument type: SHARE

ISIN: FI4000507934

Nature of transaction: ACQUISITION

Transaction details

(1): Volume: 300 Unit price: 1.79 EUR

Aggregated transactions (1)

Volume: 300 Volume weighted average price: 1.79 EUR

Further inquiries 

Antti Ojala, CFO, Aiforia Technologies Plc
tel. +358 40 7202448
https://investors.aiforia.com/

Certified Adviser 

UB Corporate Finance Ltd

ubcf@unitedbankers.fi

About Aiforia

Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.

Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France, and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient.

Find out more at www.aiforia.com